Nanexa files a new patent application
Nanexa strengthens its patent portfolio by filing a further patent application to the UK Patent Office. The patent application relates to an invention linked to Nanexa’s drug delivery system PharmaShell®.
The continuous development work with PharmaShell® has resulted in a new invention that falls within the framework of Nanexa’s drug delivery system PharmaShell®. The patent application, in addition to the product, also refers to the method of manufacture and applications.
The application was filed at the UK Patent Office on December 14, 2017 and was assigned Application Number 1720891.9. Within the priority year, there is an opportunity to follow up the British patent application with an international patent application (PCT application), which Nanexa also intends to do.
The company’s CEO David Westberg comments:
“Intellectual property in general and patents in particular is very important for Nanexa’s business. Through this new patent application, we further strengthen the protection of PharmaShell®.”
For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail: firstname.lastname@example.org
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.